Metabolic and pharmacokinetic differentiation of STX209 and racemic baclofen in humans

Metabolites

Volumn 2, Issue 3, 2012, Pages 596-613

  Sanchez Ponce, Raymundo ^a   Wang, Li Quan ^b   Lu, Wei ^b   von Hehn, Jana ^a   Cherubini, Maryann ^a   Rush, Roger ^a  

^a Seaside Therapeutics Inc   (United States)

^b XENOBIOTIC LABORATORIES INC   (United States)

Author keywords

Baclofen; Metabolic differentiation; Pharmacokinetics; R baclofen

Indexed keywords

ARBACLOFEN; BACLOFEN; GLUCURONIDE;

ARTICLE; AUTISM; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOMER; FRAGILE X SYNDROME; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIMIT OF QUANTITATION; MASS FRAGMENTOGRAPHY; NORMAL HUMAN; PLASMA CLEARANCE; RACEMIC MIXTURE;

EID: 84894425134     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo2030596     Document Type: Article

References (29)

1. Seaside Therapeutics, Available online: http://www.seasidetherapeutics.com/ (accessed on 5 September 2012).
2. Wuis, E.W.; Dirks, M.J.; Termond, E.F.; Vree, T.B.; Van der Kleijn, E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur. J. Clin. Pharmacol. 1989, 37, 181-184.
3. Faigle, J.W.; Keberle, H. The chemistry and kinetics of lioresal. Postgrad Med. J. 1972, 48 (Suppl. 5), 9-13.
4. Faigle, J.W.; Keberle, H.; Gegen, P.H. Chemistry and pharmacokinetics of baclofen. In Spasticity: Disorder Motor Control; Feldman, R.G., Young, R.R., Koella, W.P., Eds.; Year Book Medical Publishers: Chicago, USA, 1980.
5. Hulme, A.; MacLennan, W.J.; Ritchie, R.T.; John, V.A.; Shotton, P.A. Baclofen in the elderly stroke patient its side-effects and pharmacokinetics. Eur. J. Clin. Pharmacol. 1985, 29, 467-469.
6. Krauss, D.; Spahn, H.; Mutschler, E. Quantification of baclofen and its fluoro analogue in plasma and urine after fluorescent derivatisation with benoxaprofen chloride and thin-layer chromatographic separation. Arzneimittelforschung 1988, 38, 1533-1536.
7. Wiersma, H.E.; van Boxtel, C.J.; Butter, J.J.; van Aalderen, W.M.; Omari, T.; Benninga, M.A. Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. Ther. Drug Monit. 2003, 25, 93-98.
8. Wuis, E.W.; Dirks, M.J.; Vree, T.B.; Van der Kleijn, E. Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses. Pharm. Weekbl Sci. 1990, 12, 71-74.
9. Wuis, E.W.; Dirks, R.J.; Vree, T.B.; van der Kleyn, E. High-performance liquid chromatographic analysis of baclofen in plasma and urine of man after precolumn extraction and derivatization with o-phthaldialdehyde. J. Chromatogr. 1985, 337, 341-350.
10. Wuis, E.W.; Dirks, M.J.; Termond, E.F.; Vree, T.B.; van der Kleijn, E. Comparison of the pharmacokinetics of intravenously administered rac-baclofen and its (-)-(r)-and (+)-(s)-enantiomers in dogs. Int. J. Clin. Pharmacol. Res. 1989, 9, 239-246.
11. Mutschler, E.; Gietl, Y.; Krasuss, D.; Martin, E.; Pflugmann, G.; Weber, H.; Spahn, H. Chirality and Biological Activity; Holmstedt, B., Hartmut, F., Bernard, T., Eds.; Alan R. Liss Inc.: New York, NY, USA, 1990; Volume19, pp 199-219.
12. Meyer, G.; Fishbein, G.; Boyd, D. Single-Dose Plasma pk parameters of arbaclofen, r-baclofen and s-baclofen. In Proceedings of 40th Annual Meeting of the American College of Clinical Pharmacology, Chicago, IL, USA, 11-13 September 2011.
13. Strober, W. Trypan blue exclusion test of cell viability. Curr. Protoc. Immunol. 2001, doi:10.1002/0471142735.ima03bs21.
14. Hop, C.E.; Wang, Z.; Chen, Q.; Kwei, G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci. 1998, 87, 901-903.
15. Abelo, A.; Andersson, T.B.; Antonsson, M.; Naudot, A.K.; Skanberg, I.; Weidolf, L. Stereoselective metabolism of omeprazole by human cytochrome p450 enzymes. Drug Metab. Dispos. 2000, 28, 966-972.
16. Schwaninger, A.E.; Meyer, M.R.; Barnes, A.J.; Kolbrich-Spargo, E.A.; Gorelick, D.A.; Goodwin, R.S.; Huestis, M.A.; Maurer, H.H. Stereoselective urinary mdma (ecstasy) and metabolites excretion kinetics following controlled mdma administration to humans. Biochem. Pharmacol. 2011, 83, 131-138.
17. Song, Y.L.; Jing, W.H.; Zhao, H.Y.; Yan, R.; Li, P.T.; Wang, Y.T. Stereoselective metabolism of (+/-)-praeruptorin a, a calcium channel blocker from peucedani radix, in pooled liver microsomes of rats and humans. Xenobiotica 2011, 43, 231-237.
18. Constantino, L.; Paixao, P.; Moreira, R.; Portela, M.J.; Do Rosario, V.E.; Iley, J. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome p450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Exp. Toxicol. Pathol. 1999, 51, 299-303.
19. Obach, R.S.; Cox, L.M.; Tremaine, L.M. Sertraline is metabolized by multiple cytochrome p450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metab. Dispos. 2005, 33, 262-270.
20. Nebert, D.W.; Russell, D.W. Clinical importance of the cytochromes p450. Lancet 2002, 360, 1155-1162.
21. Ding, X.; Kaminsky, L.S. Human extrahepatic cytochromes p450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 149-173.
22. Seliskar, M.; Rozman, D. Mammalian cytochromes p450--importance of tissue specificity. Biochim. Biophys. Acta 2007, 1770, 458-466.
23. Saura, J.; Nadal, E.; van den Berg, B.; Vila, M.; Bombi, J.A.; Mahy, N. Localization of monoamine oxidases in human peripheral tissues. Life Sci. 1996, 59, 1341-1349.
24. Rodriguez, M.J.; Saura, J.; Billett, E.E.; Finch, C.C.; Mahy, N. Cellular localization of monoamine oxidase a and b in human tissues outside of the central nervous system. Cell Tissue Res. 2001, 304, 215-220.
25. Ramonet, D.; Rodriguez, M.; Saura, J.; Lizcano, J.M.; Romera, M.; Unzeta, M.; Finch, C.; Billett, E.; Mahy, N. Localization of monoamine oxidase a and b and semicarbazide-sensitive amine oxidase in human peripheral tissues. Inflammopharmacology 2003, 11, 111-117.
26. Lal, R.; Sukbuntherng, J.; Tai, E.H.; Upadhyay, S.; Yao, F.; Warren, M.S.; Luo, W.; Bu, L.; Nguyen, S.; Zamora, J.; et al., Arbaclofen placarbil, a novel r-baclofen prodrug: Improved absorption, distribution, metabolism, and elimination properties compared with r-baclofen. J. Pharmacol. Exp. Ther. 2009, 330, 911-921.
27. Olpe, H.R.; Demieville, H.; Baltzer, V.; Bencze, W.L.; Koella, W.P.; Wolf, P.; Haas, H.L. The biological activity of d-and l-baclofen (lioresal). Eur. J. Pharmacol. 1978, 52, 133-136.
28. Johnston, G.A.; Hailstone, M.H.; Freeman, C.G. Baclofen: Stereoselective inhibition of excitant amino acid release. J. Pharm. Pharmacol. 1980, 32, 230-231.
29. Hill, D.R.; Bowery, N.G. 3h-baclofen and 3h-gaba bind to bicuculline-insensitive gaba b sites in rat brain. Nature 1981, 290, 149-152.